Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

Connect Biopharma: New Market Opportunity In The Emergency Setting

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript

Connect Biopharma Announces $20.2 Million Private Placement Financing

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference

BML Capital Management LLC Sells 554,058 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of “Moderate Buy” by Analysts

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives Average Rating of “Moderate Buy” from Brokerages

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Holdings Limited (CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases Transcript

Analyzing Connect Biopharma (CNTB) & Its Rivals

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Connect Biopharma to Present at Two Upcoming Investor Conferences

Attovia Therapeutics Appoints Chief Financial Officer

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update